» Articles » PMID: 8842276

Cryptococcus Neoformans Infection in France: Epidemiologic Features of and Early Prognostic Parameters for 76 Patients Who Were Infected with Human Immunodeficiency Virus

Overview
Journal Clin Infect Dis
Date 1996 Aug 1
PMID 8842276
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

We retrospectively carried out a descriptive and prognostic study of 76 human immunodeficiency virus-infected patients with cryptococcosis diagnosed by a positive culture of cerebrospinal fluid (CSF), blood, urine, or other body fluid or tissue. We focused on the 65 patients with cryptococcal meningitis. At diagnosis, the mean CD4 lymphocyte count was 46/mm3; 86% of patients had fever; 67%, headache; 37%, stiff neck; 29%, altered mentation or confusion; 20% cranial nerve deficiency; and 48%, other focal deficiencies. Analysis of CSF specimens revealed the following results: normal (25% of the specimens), leukocyte count of < 20/mm3 (62%), positive India ink smear (87%), and positive cryptococcal antigen (92%). Twenty patients died within the first 3 months (3-month survival rate, 70%). A Cox regression model selected the following as prognostic parameters: age older than 30 years (relative risk [RR] = 2.1), CSF glucose level of < 2 mmol/L (RR = 3.7), previous admission to an intensive care unit (RR = 4.7), and mechanical ventilation (RR = 4.6). The outcome of cryptococcal meningitis in patients with AIDS remains difficult to predict at admission, and every case should be considered as potentially severe.

Citing Articles

Machine learning-based prognostic prediction for hospitalized HIV/AIDS patients with cryptococcus infection in Guangxi, China.

Zhan B, Wei W, Xie Z, Meng S, Bao X, He X BMC Infect Dis. 2024; 24(1):1121.

PMID: 39379851 PMC: 11459777. DOI: 10.1186/s12879-024-10013-y.


Clinical treatment of cryptococcal meningitis: an evidence-based review on the emerging clinical data.

Liu M, Dai X, Zeng M, Chen E J Neurol. 2024; 271(6):2960-2979.

PMID: 38289535 DOI: 10.1007/s00415-024-12193-8.


Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?.

Ngan N, Flower B, Day J Drugs. 2022; 82(12):1237-1249.

PMID: 36112342 PMC: 9483520. DOI: 10.1007/s40265-022-01757-5.


in Patients with Lymphoid Neoplasms: An Illustration of Evolutive Host-Fungus Interactions.

Paccoud O, Bougnoux M, Desnos-Ollivier M, Varet B, Lortholary O, Lanternier F J Fungi (Basel). 2021; 7(3).

PMID: 33809570 PMC: 8001097. DOI: 10.3390/jof7030212.


Prediction of unfavorable outcomes in cryptococcal meningitis: results of the multicenter Infectious Diseases International Research Initiative (ID-IRI) cryptococcal meningitis study.

Hakyemez I, Erdem H, Beraud G, Lurdes M, Silva-Pinto A, Alexandru C Eur J Clin Microbiol Infect Dis. 2017; 37(7):1231-1240.

PMID: 29218468 DOI: 10.1007/s10096-017-3142-1.